Pip Nicolson/X
Jun 6, 2025, 10:56
Pip Nicolson Highlights Key PITT Case Insight on Anti-PF4 Antibody Testing
Pip Nicolson, Associate Clinical Professor in Cardiovascular Medicine (Haematology) at University of Birmingham, shared on X:
“Thank you Prof. Makris for your clear and concise commentary on our PITT case in the British Journal of Hematology.
Take home message: test anyone with the combination of thrombosis and thrombocytopenia for anti-PF4 antibodies (by ELISA) and have a low threshold for starting non-heparin anticoagulation.”
You Can Find More Posts Featuring Pip Nicolson on Hemostasis Today.
Title: PF4-associated immune thrombocytopenia and thrombosis (PITT)—More than heparin and vaccines
Author: Michael Makris
-
Dec 20, 2025, 18:30Kate Scrivener on Cochrane Review: 2025 Ends With a Big Milestone!
-
Dec 20, 2025, 18:15Shekher Bose on AstraZeneca’s Voluntary Withdrawal of Andexxa
-
Dec 20, 2025, 17:10Mina Adel Nagi on the Future of ESR Testing with HORIBA’s CoRA Technology
-
Dec 20, 2025, 16:50Geert Verheyden on Advancing Stroke Rehabilitation Through Collaboration and Innovation
-
Dec 20, 2025, 16:26Dirk Sibbing on Antithrombotic Drugs for ACS in Women
-
Dec 20, 2025, 16:13Akshat Jain Explains VWF/FVIII Prophylaxis in Children Under 6
-
Dec 20, 2025, 15:49Manuel Requena Shares The Results of the RESISTANT International Registry
-
Dec 20, 2025, 13:49Harshal Kale: Wishing Our Community a Bright Start to 2026
-
Dec 20, 2025, 12:23Healthcare is a Human Right: Strengthening Blood Donation in Armenia